久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • The R&D of CD20/CD3 Bispecific Antibody in China Yefenghong/PharmaSources
    March 01, 2023
    Currently, the R&D of CD20/CD3 bispecific antibody is still in the early stage. In China, few CD20/CD3 bispecific antibodies have entered the clinical stage, among which GB261 from Genor Biopharma has a good progress.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service